skip to main content

HMT-3522 T4-2

HMT-3522 T4-2

Catalogue No.


Cell Line Name

HMT-3522 T4-2

Cell Line Description

HMT-3522 T4-2, also known as HMT-3522/mt-1, is a subline that has been derived from HMT-3522. The parent line was established from a benign breast tumour of a 48 year old woman and has undergone spontaneous malignant transformation. It was grown on collagen in serum-free media without antibiotics from explantation onwards. A mutation at codon 179 of the p53 gene was detected during establishment of the parent line at passage 25-30. The subline S1 is a continuation of this line from passage 34 (ECACC cataogue no. 98102210) growing without collagen. Subline S2 (ECACC catalogue no. 98102211) has been isolated by culturing S1 cells from passage 118 in serum-free media without epidermal growth factor (EGF). The third subline, T4-2 was established from S2 at passage 238 and is the only tumorigenic line in nude mice out of the 3 sublines. S2 and T4-2 grow on collagen-coated flasks. The dramatic shift in phenotype between S2 and T4-2 was followed by a single cytogenetic change, the gain of an extra copy of the marker chromosome 7q- leading to trisomy for the short arm of chromosome 7 in T4-2 cells. Expression of cytokeratin 13, 14, 17 and 18, vimentin and sialomycin has been reported as well as mRNA for EGF receptor and TGFalpha. The expression of p53 mRNA is higher in T4-2 compared to S2. The cells have been tested positive for EGF receptor but negative for estrogen receptor. In a three-dimensional basement membrane culture assay the phenotypic characteristics of malignant breast tissue in vivo are recapitulated. A reduction of beta1-cell surface integrin activity by blocking antibodies was found to be sufficient to revert the tumour phenotype. Publications using this cell line must refer to the original paper (Briand et al., In Vitro Cell Dev Biol 1987; 23:181). Any sublines created must include the name €œHMT-3522€ in the designation, but a short name may be used in the same paper.




Tissue of Origin


DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 11,12
D5S818: 9,11
D7S820: 8,9
D13S317: 11
D16S539: 11,13
TH01: 9,9.3
TPOX: 8,11
vWA: 14,17




Evolution of karyotype and growth factor requirements, model for premalignant breast epithelium and study of mechanism of malignant conversion



Culture Conditions

Cell Type


Subculture Routine

If starting from a frozen ampoule the cryoprotectant should be removed. Add thawed cells to a conical based centrifuge tube e.g. 15ml tube, slowly add 4 ml of culture medium to the tube. Take a sample of the cell suspension, e.g. 100µl, to count cells. Centrifuge the cell suspension at low speed i.e. 100 - 150 x g for a maximum of 5 minutes. Seed pre-coated flasks between 2-4 x10,000 cells/cm². Split sub-confluent cultures (70-80%) 1:5 to 1:10 using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Cells detach slowly; add same volume of trypsin inhibitor as trypsin used before, centrifuge and reseed cells in collagen IV coated flasks. Medium is serum-free, therefore trypsin inhibitor is essential. Cells should be frozen in (45% conditioned media : 45% fresh media) with 10% DMSO.

Culture Medium

DMEM / Ham's F12 (1:1) + 2mM Glutamine + 250ng/ml insulin + 10µg / ml transferrin +10⁻⁸M Sodium selenite + 10⁻¹⁰M 17 β-estradiol + 0.5µg/ml hydrocortisone + 5µg / ml ovine prolactin

Growth Mode


Additional Info


Dr P Briand, Department of Tumour Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark

Country of Origin


Hazard Group (ACDP)

Hazard Group (ACDP) 2



In Vitro Cell Dev Biol 1987; 23:181; Exper Cell Res 1994;215:380; Cancer Res 1996;56:2039; J Cell Biol 1997; 137: 231; Genes Chromosom Cancer 1997; 20: 30; Nat Biotechnol 1997; 15: 517

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: HMT-3522 T4-2 (ECACC 98102212).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.